Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Xencor has commenced the Phase 1 clinical trial of XmAb5871, a therapeutic antibody used to treat autoimmune diseases like Lupus and Rheumatoid Arthritis
Subscribe to our email newsletter
XmAb5871, a humanized monoclonal antibody using selective dual-targeting mechanism for B cell inhibition by targeting the antigen CD19 and co-engaging CD32b (Fc?RIIb), helps in suppression of autoimmune response.
Preclinical studies demonstrated that XmAb5871 suppresses autoimmune response in humanized mouse models of systemic lupus erythematosus (SLE), without the depletion of B cells.
The endpoints of the Phase 1 study are safety, pharmacokinetics and a number of biomarkers of immunomodulatory drug activity.